axendia

Interview on Closed-Loop Quality Execution and Continuous Innovation

2008-09-04T21:00:00Z

During a recent interview, the folks at Camstar asked that I share my thoughts on the impact that Closed-Loop Quality Execution on Life Sciences Manufacturing in the “Age of Continuous Innovation”.

Visit Axendia's Life-Science Panorama to see the full interview.

Regulatory Compliance - Nature or Nurture?

2008-08-09T00:09:00Z

Individual and organizational responses to regulatory compliance fall into one of four categories.

The great philosopher “GI Joe” said “knowing is half the battle.” Understanding an individual’s tendency toward regulatory compliance can help you choose the best approach to presenting and addressing compliance issues.

So, are you a Contrarian, a Zealot, a Rationalist or Illusionned?

Visit Axendia's Life-Science Panorama to read the full article.

Axendia’s President to Chair 3rd Annual MES for Life Sciences Congress

2008-07-09T17:25:00Z

YARDLEY, Pa. and WOBURN, Mass., July 9, 2008 -- Axendia Inc., a trusted advisor to Life-Science Executives on Business, Technology and Regulatory strategies, and CBI Research Inc., a provider of live and electronic conferences for senior-level executives in the pharmaceutical and biotech industries, today announced that Daniel R. Matlis President and Founder of Axendia, will chair CBI's "3rd Annual Manufacturing Execution Systems for Life Sciences Congress" to be held on August 5 - 6, 2008 in Philadelphia, PA.

Over 500 pharmaceutical, biotech and medical device executives have benefited from the Manufacturing Execution Systems (MES) Conference. The 3rd Annual meeting convenes manufacturing decision-makers from the pharmaceutical, biotech and medical device communities.

Visit Axendia's Life-Science Panorama to read the full article

Color and Glass Brighten a Sterile Facility, Lessons from IDT Biologika

2008-06-16T23:46:00Z

Sterile Manufacturing facilities are often, well sterile. They are typically comprised of drab clean-rooms where the color palette is limited to stainless steel and shades of grey.

For this installment of our “2008 Learning from Success” series, I had the privilege of speaking with Dr. Ralf Pfirmann, Managing Director of IDT Biologika’s site in Dessau-Rosslau, Germany. IDT’s new vaccine manufacturing site received the 2008 Facility of the Year Award for Operational Excellence.

Visit Axendia's Life-Science Panorama to read the full article

First Standardized Branded, Pharmaceutical Grade Placebo

2008-05-28T14:11:00Z

For years I have been joking about some company marketing a sugar pill based on clinical trial data supporting the “placebo effect”.

I never thought I would see the day when this prediction would come true.

Well, today is the day. Efficacy Brands LLC has begun selling Obecalp “…the First Standardized Branded and Pharmaceutical Grade Placebo…”

Visit Axendia's Life-Science Panorama to read the full article

Building a Winning Facility with Sweat Equity, Lessons from Bristol-Myers Squibb

2008-05-22T12:10:00Z

For this installment of our “2008 Learning from Success” series, I had the privilege of speaking with Mark Wagner, Vice President Worldwide Clinical Supply Operations and Sarah K. Doshna Associate Director, Parenteral Manufacturing Pharmaceutical Research Institute. They represented Bristol-Myers Squibb (BMS), the winner of the 2008 Facility of the Year Award for Equipment Innovation.

Visit Axendia's Life-Science Panorama to read the full article

Shifting from CACA to PACA

2008-05-08T20:15:00Z

No, it is not a typo; I mean to spell it C-A-C-A.

Last week, I had the opportunity to present at Camstar’s 2008 “Vision to Value” Manufacturing 360 Customer Conference. One of my sessions was entitled “Shifting from CAPA to PACA”. The takeaway message was simple: Our industry must move from the current Reactive “Corrective and Preventive Action” (CAPA) to a proactive “Preventive and Corrective Action” (PACA) approach of Quality management.

Visit Life-Science Panorama to read the full article

The Age of Continuous Innovation

2008-04-22T23:00:00Z

Last week, I was asked me to provide my thoughts before the release of their new eBook entitled “Winning Profit in the Age of Continuous Innovation”

As I read the eBook I kept thinking about Heraclitus’ famous refrain: “The only constant is change.”

In this century, with the increasing rate of scientific knowledge, information has become ubiquitous. Innovation has taken its place as the fuel for the growth engine.

Visit Life-Science Panorama to read the full article

Learning from Success – 2008 Pharmaceutical FOYA Winners

2008-04-09T20:04:00Z

During Interphex 2008, I had the opportunity to interview the winners of the Forth annual Facility of the Year Awards (FOYA) competition, sponsored by ISPE, INTERPHEX, and Pharmaceutical Processing magazine.

The wining companies were:

Boehringer Ingelheim Pharma GmbH & Co.KG,
Bristol-Myers Squibb,
IDT Biologika GmbH,
F. Hoffmann La Roche AG,

I was very encouraged to hear many of the same themes as I spoke with representatives from the winning teams...

Visit Life-Science Panorama to read the full article

A Broken Pipeline

2008-03-12T21:42:00Z

Yesterday, a group of seven leading academic research institutions issued a report entitled “A Broken Pipeline? Flat Funding of the NIH Puts a Generation of Science at Risk.”

The report was co-authored by Brown University, Duke University, Harvard University, The Ohio State University, Partners Healthcare, the University of California Los Angeles, and Vanderbilt University.

Visit Life-Science Panorama to read the full article

Robots Building People

2008-03-06T17:27:00Z

No it is not the title of the latest sci-fi blockbuster film, but one of the lessons I learned from FIRST.

Last week I had the opportunity; no the privilege, of being a judge at the “2008 New Jersey Regional FIRST Robotics Competition (FRC).”

FIRST (For Inspiration and Recognition of Science and Technology) was founded in 1989 by Dean Kamen to inspire young people’s interest and participation in science and technology.

Visit Life-Science Panorama to read the full article

Managing Documents and Records, The Never-ending Process

2008-02-27T16:55:00Z

That was the theme of the 21st annual DIA Conference for Electronic Document Management (EDM) hosted in Philadelphia on February 5 through 8. The goal of this year’s conference was to focus on grass roots; getting back to basics and best practices. While the intent was not specifically about the transformation to an electronic ‘state’ and the associated evolving standards, it was evident many attendees still want to know how to get there. The overarching theme for the conference was the “Never-ending Process”.

Read the complete story

Supreme Court Shields Medical-Device Makers

2008-02-22T12:15:00Z

In its February 20, 2008, decision in Riegel v Medtronic, Inc., the U.S. Supreme Court ruled that The Medical Devices Act of 1976 (“MDA”) was sufficient to preempt any State law that purported to “establish or continue … any requirement … which is different from, or in addition to, any requirement” under relevant federal law.

Read the complete story

The State of Outsourcing in Life-Sciences

2008-02-19T21:02:00Z

Lately, I have been getting a lot of questions regarding the state of Outsourcing in Life-Sciences.

When I started working in Life-Sciences, nearly two decades ago, going offshore meant moving operations to a company owned facility in Puerto Rico. This was the heyday of Section 936. Established in 1976, Section 936 of the Internal Revenue Code provided U.S. firms operating in Puerto Rico with tax-free income. Lower wages and the security of being home (Puerto Rico is a free associated state of the US) made the island a hub of Life-Science activities.

Read the complete story

Congress Asks the GAO to Examine Deficiencies in FDA IT Systems

2008-01-31T23:14:00Z

Yesterday, Representative Henry A. Waxman and Senator Edward Kennedy issued a letter asking the General Accounting Office (GAO) to conduct an examination FDA’s staffing, information technology, and other resources necessary for the agency to successfully carry out its oversight of foods, drugs, biologics, and medical devices.

A stated goal of the GAO assessment is to “fully understand the extent to which deficiencies in FDA's IT systems impair the agency's ability to execute its mission, and the actions and resources necessary to correct those deficiencies.”

Read complete story